Indeed, ASCT2 knock down has been reported to strongly decrease mTORC1 activity and tumor growth in multiple xenograft models suggesting that ASCT2 may be, as well, a good therapeutic target for cancer therapy [43,44,45]. Here, SLC1A5 is linked to neoplasm.